venice ii trial: health-related qol in patients with cll treated with venetoclax
Published 10 months ago • 75 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
4:38
venice i: venetoclax in r/r cll patients
-
1:53
venice i: mrd response with venetoclax in r/r cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
3:33
investigating the safety and efficacy of re-treating cll patients with venetoclax-based regimens
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:00
clarity: a phase 2 trial using venetoclax and ibrutinib
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
3:08
recent updates on tp53 mutation in cll
-
5:00
venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:57
murano trial: duvelisib plus venetoclax in r/r cll, sll and richter’s syndrome
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:09
overview of the cll13 trial: replacing chemotherapy with venetoclax-containing regimens
-
3:44
the cll2-bag trial: discovering an effective treatment for cll
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:28
the future of cll treatment
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
0:51
long-term post hoc analysis of murano trial: host immune changes following venr treatment in cll